Oral Wegovy Side Effects: Nausea & Warnings (2026)

01

The most common oral Wegovy side effects

In the pivotal OASIS 4 trial of oral semaglutide 25 mg versus placebo, gastrointestinal reactions were the most frequently reported side effects, and they were clearly dose-related — clustering around dose escalation and mostly mild-to-moderate and transient. Per Novo Nordisk's OASIS 4 data presented at ObesityWeek 2025 and the FDA approval coverage, the two most common events were:

(Source: OASIS 4 trial, oral semaglutide 25 mg. Individual experience varies.)

Beyond nausea and vomiting, the FDA Wegovy label and Novo Nordisk safety information list the following as the most common side effects for semaglutide (shared across the oral and injectable forms): nausea, diarrhea, vomiting, constipation, abdominal pain, changes in skin sensations, headache, fatigue, upset stomach (dyspepsia), dizziness, bloating, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu (gastroenteritis), heartburn, and hair loss.

Crucially, in OASIS 4 the GI events were mostly mild-to-moderate, and discontinuation for adverse events was low — about 6.9% on oral semaglutide 25 mg versus 5.9% on placebo, a small gap that underscores how most people tolerated the medicine well enough to continue.

Oral Wegovy nausea

Nausea is the single most common oral Wegovy side effect — reported by roughly 46.6% of people in OASIS 4 versus 18.6% on placebo.

As with the injection, it typically peaks around dose increases and then settles as the body adjusts.

Clinics such as Cleveland Clinic note that eating smaller, lower-fat meals, eating slowly, stopping at the first feeling of fullness, and sipping fluids between meals are common ways to ease GLP-1 nausea.

Greasy, fried, and very sweet foods tend to make it worse.

Vomiting, diarrhea, and constipation

Vomiting was reported by about 30.9% in OASIS 4 (versus 5.9% on placebo).

Vomiting and diarrhea share a practical risk: dehydration. Because semaglutide also blunts thirst and appetite, it is easy to under-drink.

Persistent vomiting or diarrhea that keeps you from holding down fluids is a reason to call your clinician — partly because severe dehydration can, in rare cases, contribute to acute kidney injury (see serious effects below).

Constipation stems from the same slowed gut motility.

Changes in skin sensations and other common effects

The oral Wegovy label lists "changes in skin sensations" (dysesthesia) among common side effects, alongside headache, fatigue, dizziness, bloating, belching, gas, heartburn, and hair loss. These are usually mild.

02

The oral angle: the empty-stomach rule and what it does (and doesn't) change

The biggest practical difference with oral semaglutide is how it must be taken, not a different set of risks.

Per the FDA oral semaglutide (Rybelsus) label, oral semaglutide must be taken on an empty stomach when you first wake, with no more than about 4 ounces of plain water, and you then wait at least 30 minutes before eating, drinking, or taking other medicines.

The tablet is swallowed whole.

Two things are important to understand here:

1. This timing affects absorption, not safety. Getting the timing right helps the medicine get into your system as intended; getting it wrong lowers how much is absorbed — it does not make the drug "safer" or eliminate the warnings below.
2. It is a daily routine, not a weekly injection. Because it is taken every day, side effects are managed through the same slow, stepwise dose increases used with the injection, and the empty-stomach window becomes part of the daily habit.

Bottom line: choosing the pill over the injection changes convenience and the daily routine, not the underlying side-effect profile or the serious warnings.

03

How long do oral Wegovy side effects last?

For most people, the common gastrointestinal side effects are temporary. In OASIS 4 they were mostly mild-to-moderate and transient, clustering around dose escalation and easing as the body adjusts — the same pattern clinics describe for GLP-1 medicines generally.

Because side effects cluster around dose changes, a slow, gradual dose escalation is the single most effective way to limit them, which is why semaglutide is titrated up in steps rather than started at the full 25 mg.

Oral Wegovy's side effects are strongly dose-dependent. The most reliable predictor of how you will tolerate it is how quickly the dose is increased, not any personal "toughness." If a step is hard, prescribers can slow the ramp — that is a clinician's decision, not a self-adjustment.

If a side effect is still severe after several weeks, that is a signal to talk with your prescriber. Do not change your own dose without medical guidance.

04

Serious oral Wegovy side effects and warnings

These are less common but important, and because oral Wegovy is the same molecule as injectable Wegovy, it carries the same serious warnings per the FDA Wegovy prescribing information.

Boxed warning: thyroid C-cell tumors

Semaglutide carries the FDA's strongest boxed warning for thyroid C-cell tumors, based on findings in rodents; whether this applies to humans is not known. Oral Wegovy is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Report a lump in the neck, trouble swallowing, shortness of breath, or persistent hoarseness.

Pancreatitis

The Wegovy label warns that acute pancreatitis has been observed with GLP-1 receptor agonists.

The classic sign is severe, persistent abdominal pain, often in the upper abdomen and sometimes radiating to the back, with or without vomiting.

Manufacturer guidance is explicit: stop the medicine and seek care promptly.

Gallbladder problems and gallstones

Treatment with semaglutide is associated with an increased occurrence of gallstones (cholelithiasis) and gallbladder inflammation, some requiring surgery.

Warning signs include pain in the upper-right abdomen, fever, yellowing of the skin or eyes (jaundice), and clay-colored stools.

Delayed gastric emptying, ileus, and aspiration risk

Semaglutide slows stomach emptying by design; the FDA added delayed gastric emptying to semaglutide labeling, and labels also list ileus (intestinal blockage). A related concern is a rare risk of pulmonary aspiration during general anesthesia or deep sedation, because food may remain in the stomach — so tell your care team you take oral Wegovy before any surgery or sedated procedure.

Kidney injury, hypoglycemia, and heart rate

There have been reports of acute kidney injury — some needing dialysis — mostly in people who became dehydrated from nausea, vomiting, or diarrhea.

On its own semaglutide carries a low hypoglycemia risk, but the risk rises with insulin or a sulfonylurea in people with type 2 diabetes.

The label also flags a modest increase in heart rate and, for people with type 2 diabetes, diabetic retinopathy monitoring.

Serious allergic reactions and mood

Serious allergic reactions can occur — stop and seek emergency care for rash, swelling of the face, lips, or throat, or trouble breathing.

As a weight-management product, the label instructs clinicians to monitor for depression or unusual mood changes. For context: after 2024 reviews, both the U.S. FDA and the European Medicines Agency concluded the evidence does not support a causal link between GLP-1 medicines and suicidal thoughts, and the FDA subsequently requested removal of that warning.

Still, report any new or worsening mood changes.

05

When to seek care: oral Wegovy red-flag table

When in doubt, call your clinician or emergency services — this table is a guide, not a substitute for professional judgment.

06

Oral Wegovy vs the injection: same molecule, different route

Oral Wegovy and injectable Wegovy are both semaglutide, so they share the same side-effect profile and the same serious warnings.

The differences are in route and daily routine, not safety category.

Because the molecule is identical, the underlying warnings are identical.

For the injection's numbers, see our Wegovy side effects guide; for the whole molecule across products, see semaglutide side effects.

07

Practical ways to reduce oral Wegovy side effects

1. Go slow. Follow the titration schedule; never rush to a higher dose on your own.
2. Eat smaller, more frequent, lower-fat meals and stop at the first sign of fullness.
3. Hydrate — sip water through the day, especially with any vomiting or diarrhea.
4. Limit greasy, fried, very sweet, and heavily processed foods, which worsen nausea.
5. Add fiber and move your body to counter constipation.
6. Prioritize protein and gradual weight loss to protect muscle and reduce hair shedding.
7. Respect the empty-stomach timing exactly as labeled, so absorption stays consistent.
8. Track your symptoms, doses, and meals — and report red-flag symptoms immediately.

Because oral Wegovy side effects cluster around specific days and doses, a simple daily log of what you feel, when you dosed, and what you ate makes conversations with your clinician far more useful.

This is exactly what the Havit app is built to make effortless — log your dose, meals, and how you feel, and see your own patterns over time. (It's a tracking companion, not a medical device — always defer to your clinician.)

08

Availability by market

Oral Wegovy (oral semaglutide 25 mg for weight management) was FDA-approved on December 22, 2025 and launched in the United States in January 2026 as the first and only oral GLP-1 for chronic weight management.

Approval in the EU and other regions is pending. In Korea, Japan, and Taiwan, the oral 25 mg weight-management pill is not yet approved — the semaglutide available there is injectable Wegovy (for weight management) or Rybelsus, a lower-dose oral semaglutide approved for type 2 diabetes.

Availability changes over time; confirm current status with a licensed clinician in your country.

09

Why HAVIT — Medication + Behavior Change, in One App

GLP-1 medications can meaningfully reduce weight — but the number on the scale is only part of the story.

Roughly 20–40% of the weight lost on GLP-1 therapy can come from lean (muscle) tissue rather than fat (Neeland et al., Diabetes, Obesity and Metabolism, 2024), and results tend to fade once the medication stops unless new habits take their place.

That's why leading guidance treats medication as one part of care, not the whole: the U.S. Preventive Services Task Force recommends that adults with obesity be offered intensive, multicomponent behavioral interventions (USPSTF, Grade B).

HAVIT is built for exactly this moment — one app that unites medication tracking, body composition, nutrition and protein, daily habit-building, and an AI coach that adapts to you.

Across our own 1,090 GLP-1 users, the most consistent trackers built the strongest habits (see the GLP-1 habit report).

Manage the medicine and the muscle — together. Start with HAVIT →

The most common oral Wegovy side effects

Related articles